Critical Reviews in Oncology / Hematology
Volume 46, Issue 3 , Pages 221-234 , June 2003

The role of pineal gland in breast cancer development

Received 1 December 2001 ,Revised 1 August 2002 ,Accepted 11 September 2002.

References 

  1. Parkin DM, Bray FI, Deseva SS. Cancer burden in the year 2000. The global picture. Eur. J. Cancer. 2000;37:S4–S66
  2. Kerenyi NA, Pandula E, Feuer G. Why the incidence of cancer is increasing: the role of ‘light pollution’. Med. Hypoth. 1990;33:75–78
  3. Stevens RG. Circadian disruption and breast cancer. In:  Bartsch C,  Bartsch H,  Blask DE,  Cardinali DP,  Hrushesky WJM,  Mecke D editor. The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer; 2001;p. 511–517
  4. Stevens RG, Rea MS. Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control. 2001;12:279–287
  5. Arendt J. Melatonin and the mammalian pineal gland. London: Chapman and Hall; 1995;
  6. Lakin-Thomas PL. Circadian rhythms: new functions for old clock genes?. Trends Gene. 2000;16:135–142
  7. Pandi-Perumal SR, Seils LK, Kayumov L, et al.  Senescence, sleep, and circadian rhythms. Ageing Res. Rev. 2002;1:559–604
  8. Hurd MW, Ralph MR. The significance of circadian organization for longevity in the golden hamster. J. Biol. Rhyth. 1998;13:430–436
  9. Thelle DS, Forde OH, Try K, Lehmann EH. The Tromso Heart Study. Acta Med. Scand. 1976;200:107–118
  10. Theorell T, Akerstedt E. Day and night work: changes in cholesterol, uric acid, glucose and potassium in serum and circadian patterns of urinary catecholamine excretion. Acta Med. Scand. 1976;200:47–53
  11. Knutsson A, Akerstedt Y, Jonsson B. Prevalence of risk factors for coronary artery disease among day and shift workers. Scand. J. Work Environ. Health. 1988;14:317–321
  12. Kawachi I, Colditz GA, Stampfer MJ, et al.  Prospective study of shift work and risk of coronary heart disease in women. Circulation. 1995;92:3178–3182
  13. Fujino Y, Mizoue T, Izumi H, Kumashiro M, Hasegawa T, Yoshimura T. Job stress and mental health among permanent night workers. J. Occup. Health. 2001;43:301–306
  14. Komarov FI, Rapoport SI, Malinovskaya NK, et al.  Ulceroprotective effect of melatonin during artificial simulation of desynchronization in rats. Vestnik. Russ. Acad. Med. Sci. 2000;8:21–25
  15. Aschoff J, von Saint Paul U, Wever R. Die Lebesdauer von Fliegen inter dem Einfluss von Zeitverschiebungen. Naturwissenschaften. 1971;58:574
  16. Sheeba V, Sharma VK, Shubha K, Chandrashekaran MK, Joshi A. The effect of different light regimes on adult life span in Drosophila melanogaster is partly mediated through reproductive output. J. Biol. Rhyth. 2000;15:380–392
  17. Hoffman JC. Light and reproduction in the rat. Effect of early lighting on response measured in adult females. Biol. Reprod. 1973;8:473–480
  18. Hoffman JC. Light and reproduction in the rat: effects of photoperiod length on albino rats from two different breeders. Biol. Reprod. 1970;2:255–261
  19. Hardy DF. The effect of constant light on the estrus cycle and behavior of the female rat. Physiol. Behav. 1970;5:421–425
  20. Murthy ASK, Russfield AB. Endocrine changes in two strains of mice exposed to constant illumination. Endocrinology. 1970;86:914–917
  21. Jochle W. Trends in photophysiologic concepts. Ann. N.Y. Acad. Sci. 1964;117:88–104
  22. Smirnova IO. Experimental Bases of Treatment of Mastopathy with Iodine Microdoses. PhD Thesis. All-Union Cancer Center, Moscow, 1966.
  23. Ird EA. Follicular cysts of the ovary and dyshormonal tumors. Leningrad: Meditsina; 1966;
  24. Lazarev NI, Ird EA, Smirnova IO. Experimental models of endocrine gynecological diseases. Moscow: Meditsina; 1976;
  25. Kothari L, Shah PN, Mhatre MC. Effect of continuous light on the incidence of 9,10-dimethyl-1,2-benzanthracene induced mammary tumors in female Holtzman rats. Cancer Lett. 1982;16:313–317
  26. Anisimov VN, Zhukova OV, Beniashvili DSh, Bilanishivili VG, Menabde MZ. Light deprivation, electromagnetic fields and mammary carcinogenesis. Adv. Pineal Res. 1994;7:229–234
  27. Brainard GC, Kaver R, Kheifets LI. The relationship between electromagnetic field and light exposure to melatonin and breast cancer risk: a review of the relevant literature. J. Pineal Res. 1999;26:65–100
  28. Coudert B. Circadian concepts in normal and neoplastic breast. Chronobiol. Int. 2002;19:221–235
  29. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocrin. Rev. 1991;12:151–180
  30. Reiter RJ. Potential biological consequences of excessive light exposure: melatonin suppression, DNA damage, cancer and neurodegenerative diseases. Neuroendocrinol. Lett. 2002;23(Suppl 2):9–13
  31. Davis , Kaune WT, Mirick DK, Chen C, Stevens RG. Residental magnetic fields, light-at-night, and nocturnal urinary 6-sulfatoxymelatonin concentration in women. Am. J. Epidemiol. 2001;154:591–600
  32. Graham C, Cook MR, Gerkovich MM, Sastre A. Examination of the melatonin hypothesis in women exposed at night to EMF or bright light. Environ. Health Perspect. 2001;109:501–507
  33. Glyckman G, Levin R, Brainrad GC. Ocular input for human melatonin regulation: relevance to breast cancer. Neuroendocrinol. Lett. 2002;23(Suppl 2):17–22
  34. Yu HS, Reiter RJ, editors. Melatonin. Biosynthesis, physiological effects, and clinical applications. Boca Raton, FL: CRC Press, 1993.
  35. Davis S, Mirck DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J. Natl. Cancer Inst. 2001;93:1557–1562
  36. Schernhammer ES, Laden F, Speizer FE, et al.  Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J. Natl. Cancer Inst. 2001;93:1563–1568
  37. Pukkala E, Auvinen H, Wahlberg G. Incidence of cancer among Finnish airline cabin attendants, 1967–92. Br. Med. J. 1995;311:649–652
  38. Tynes T, Hannevik M, Andersen A, Vistnes A, Haldorsen T. Incidence of breast cancer in Norwegian female radio and telegraph operators. Cancer Causes Control. 1996;7:197–204
  39. Hansen J. Increased breast cancer risk among women who work predominantly at night. Ann. Epidemiol. 2001;12:74–77
  40. Rafnsson V, Tulinius H, Jonasson J, Hrafnkelsson J. Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Cause Control. 2001;12:95–101
  41. Cohen M, Lippman M, Chabner R. Role of pineal gland in aetiology and treatment of breast cancer. Lancet. 1978;2:814–816
  42. Stevens RG, Davis S. The melatonin hypothesis: electric power and breast cancer. Environ. Health Perspect. 1996;104(Suppl 1):135–140
  43. Aschheim P. In:  Everitt AV,  Burgess JA editor. Aging in the hypothalamic–hypophyseal–ovarian axis in the rat. Springfield: Charles C Tomas; 1976;p. 376–392
  44. Anisimov VN. Blastomogenesis in persistent-estrus rats. Vopr. Onkol. 1971;8:67–75
  45. Anisimov VN. Carcinogenesis and aging. 2. Boca Raton: CRC Press; 1987;
  46. Dilman VM, Anisimov VN. Hypothalamic mechanisms of ageing and of specific age pathology-I. Sensitivity threshold of hypothalamo–pituitary complex to homeostatic stimuli in the reproductive system. Exp. Gerontol. 1979;14:161–174
  47. Dilman VM. Development, aging and disease. A new rationale for an intervention strategy. Chur: Harwood Academic; 1994;
  48. Rossmanith WG. Gonadotropin secretion during aging in women: review article. Exp. Gerontol. 1996;30:369–381
  49. Baturin DA, Alimova IN, Anisimov VN, et al.  Effect of light regime and melatonin on the development of spontaneous mammary tumors in HER-2/neu transgenic mice is related to a downregulation of HER-2/neu gene expression. Neuroendocr. Lett. 2001;22:439–445
  50. Bartsch C, Bartsch H. Effects of melatonin and constant light on the development of spontaneous endometrial carcinomas in aging BDII/Han rats appear to be exerted by modulation of maturation of the reproductive system. Z. Gerontol. Geriatr. 1999;32(Suppl 2):II/5
  51. Dauchy RT, Sauer LA, Blask DE, Vaughan GM. Light contamination during the dark phase in photoperiodically controlled animal rooms: effect on tumor growth and metabolism in rats. Lab. Anim. Sci. 1997;47:511–517
  52. Khaetski IK. Effect of hypothalamo-pituitary lesions induced by constant illumination on development of induced mammary tumors in rats. Vopr. Eksp. Onkol. (Kiev). 1965;1:87–93
  53. Hamilton T, Sneddon A. Environmental light and DMBA-induced rat mammary tumours. Br. J. Surg. 1968;55:71–76
  54. Hamilton T. Influence of environmental light and melatonin upon mammary tumour induction. Br. J. Surg. 1969;56:764–766
  55. Bell JA, Sneddon A, Hamilton T. Influence of light and 9,10-dimethylbenz(a) anthracene on rat ovarian steroidogenesis: neutral steroids. Biochem. J. 1968;110:29p–30p
  56. Smyth BJ, Sneddon A, Hamilton T. Influence of light and 9,10-dimethylbenz(a)-anthracene on rat ovarian steroidogenesis: phenolic steroids. Biochem. J. 1968;110:28p–29p
  57. Kothari L. Effect of melatonin on the mammary gland morphology, DNA synthesis, hormone profiles and incidence of mammary cancer in rats. In:  Gupta D,  Attanasio A,  Reiter RJ editor. The pineal gland and cancer. London: Brain Research Promotion; 1988;p. 210–219
  58. Jull JW. The effect of infection, hormonal environment, and genetic constitution on mammary tumor induction in rats by 7,12-dimethylbenz(a)anthracene. Cancer Res. 1966;26:2368–2373
  59. Shah PN, Mhatre MC, Kothari L. Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res. 1984;44:3403–3407
  60. Mhatre MC, Shah PN, Juneja HS. Effect of varying photoperiods on mammary morphology, DNA synthesis and hormonal profile in female rats. J. Natl. Cancer Inst. 1984;72:1411–1416
  61. Anderson LE, Morris JE, Sasses LB, Stevens RG. Effect of constant light on DMA mammary tumorigenesis in rats. Cancer Lett. 2000;148:121–126
  62. Russo IH, Russo J. Mammary gland neoplasia in long-term rodent studies. Environ. Health Perspect. 1996;104:938–967
  63. Blask DE. An overview on the neuroendocrine regulation of experimental tumor growth by melatonin and its analogues and the therapeutic use of melatonin in oncology. In:  Bartsch C,  Bartsch H,  Blask DE,  Cardinali DP,  Hrushesky WJM,  Mecke D editor. The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer; 2001;p. 309–342
  64. Travlos GS, Wilson RE, Murrell JA, Chignell CF, Boorman GA. The effect of short intermittent light exposures on the melatonin circadian rhythm and NMU-induced breast cancer in female F344/N rats. Toxicol. Pathol. 2001;29:126–136
  65. Van den Heiligenberg S, Depres-Brummer P, Barbason H, Claustrat B, Reynes M, Levi F. The tumor promoting effect of constant light exposure on diethylnitrosamine-induced hepatocarcinogenesis in rats. Life Sci. 1999;64:2523–2534
  66. Beniashvili DS, Benjamin S, Baturin DA, Anisimov VN. Effect of light/dark regimen on N-nitrosoethylurea-induced transplacental carcinogenesis in rats. Cancer Lett. 2001;163:51–57
  67. Kuralasov AK. Effect of dark adaptation on carcinogenesis and efficacy of treatment DMBA-induced mammary tumor. Izvestia Akad. Nauk. Kazakh. SSR Ser. Biol. 1979;4:79–82
  68. Kuralasov AK. Experimental Bases for Application of Artificial Photoregimen for Breast Cancer Treatment in Kazakhstan. Diss Doctor Med Sci. Moscow: All-Union Cancer Center, 1990.
  69. Blask DE, Hill SM, Pelletier DB. Oncostatic signaling by the pineal gland and melatoninin the control of breast cancer. In:  Gupta D,  Attanasio A,  Reiter RJ editor. The pineal gland and cancer. London: Brain Research Promotion; 1988;p. 221–232
  70. Blask DE. The pineal: an oncostatic gland. In:  Reiter RJ editors. The pineal gland. New York: Raven Press; 1984;p. 253–284
  71. Sanchez-Barcelo EJ, Cos S, Mediavilla MD. Influence of pineal function on the initiation and growth of hormone-dependent breast tumors. Possible mechanisms. In:  Gupta D,  Attanasio A,  Reiter RJ editor. The pineal gland and cancer. London: Brain Research Promotion; 1988;p. 221–232
  72. Hahn RA. Profound bilateral blindness and the incidence of breast cancer. Epidemiology. 1991;2:108–210
  73. Feychting M, Oosterlund B, Ahlbom A. Reduced cancer incidence among the blind. Epidemiology. 1998;9:490–494
  74. Pukkala E, Verkasalo PK, Ojamo M, Rudanko SL. Visual impairment and cancer: a population-based cohort study in Finland. Cancer Causes Control. 1999;10:13–20
  75. Verkasalo PK, Pukkala E, Stevens RG, Ojamo M, Rudanko SL. Inverse association between breast cancer incidence and degree of visual impairment in Finland. Br. J. Cancer. 1999;80:1459–1460
  76. Cos S, Sanchez-Barcel EJ. Melatonin and mammary pathological growth. Front. Neuroendocrinol. 2000;21:133–170
  77. Cos S, Sanchez-Barcelo EJ. In vitro effects of melatonin on tumor cells. In:  Bartsch C,  Bartsch H,  Blask DE,  Cardinali DP,  Hrushesky WJM,  Mecke D editor. The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer; 2001;p. 221–239
  78. Blask DE, Hill SM. Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. J. Neural. Transm. (Suppl). 1986;21:433–449
  79. L'Hermite-Baleriaux M, de Launoit Y. Is melatonin really an in vitro inhibitor of human breast cancer cell proliferation in vitro. Cell Dev. Biol. 1992;28A:583–584
  80. Molis T, Walters MR, Hill SM. Melatonin modulation of estrogen receptor expression in MCF-7 human breast cells. Int. J. Oncol. 1993;3:687–694
  81. Lemus-Wilson A, Kelly PA, Blask DE. Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. Br. J. Cancer. 1995;72:1435–1440
  82. Haus E, Dumitriu L, Nicolau GY, Bologa S, Sackett-Lundeen L. Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer. Chronobiol. Int. 2001;18:709–727
  83. Anisimov VN, Morozov VG, Khavinson VKh, Dilman VM. Correlation of anti-tumor activity of pineal and hypothalamic extracts, melatonin and sygetin in mouse transplantable mammary tumor. Vopr. Onkol. 1973;10:99–101
  84. Aubert C, Janiaud P, Lecalvez J. Effect of pinealectomy and melatonin on mammary tumor growth in Sprague–Dawley rats under different conditions of lighting. J. Neural. Trans. 1980;47:121–130
  85. Blask DE, Hill SM, Orstead KM, Massa JS. Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotion phase of 7,12-dimethylbenz[a]-anthracene-(DMBA)-induced mammary tumorigenesis. J. Neural. Transm. 1986;67:125–138
  86. Kothari L. Influence of chronic melatonin on 9,10-dimethyl-1,2-benzanthrazene-induced mammary tumors in female Holtzman rats exposed to continuous light. Oncology. 1987;44:64–66
  87. Subramanian A, Kothari L. Suppressive effect by melatonin on different phases of 9,10-dimethyl-1,2-benzathracene (DMBA)-induced rat mammary gland carcinogenesis. Anticancer Drugs. 1991;2:297–303
  88. Tamarkin L, Cohen D, Roselle C, Reichert M. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the rat. Cancer Res. 1981;41:4432–4436
  89. Welsch CW. Host factors affecting the growth of carcinogen-induced rats mammary carcinomas: a review and tribute to Charles Benton Huggins. Cancer Res. 1985;45:3415–3443
  90. Blask DE, Pelletier DB, Hill SM, et al.  Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo. J. Cancer Res. Clin. Oncol. 1991;117:526–532
  91. Kothari A, Borges A, Kothari L. Chemoprevention by melatonin and combined melatonin-tamoxifen therapy of second generation nitroso-methylurea-induced mammary tumour in rats. Eur. J. Cancer Prev. 1995;4:497–500
  92. Kothari A, Borges A, Ingle A, Kothari L. Combination of melatonin and tamoxifen as a chemoprophylaxis against N-nitroso-N-methylurea-induced rat mammary tumors. Cancer Lett. 1997;111:59–66
  93. Kubatka P, Bojkova B, Mocikova-Kalicka K, et al.  Effect of tamoxifen and melatonin on mammary gland cancer induced by N-methyl-N-nitrosourea and by 7,12-dimethylbenz(a)-anthracene, respectively, in female Sprague–Dawley rats. Folia Biol. 2001;47:5–10
  94. Subramanian A, Kothari L. Melatonin, a suppressor of spontaneous murine mammary tumors. J. Pineal Res. 1991;10:136–140
  95. Anisimov VN, Zavarzina NY, Zabezhinski MA, et al.  Melatonin increases both life span and tumor incidence in female CBA mice. J. Gerontol. Biol. Sci. 2001;56A:B311–B323
  96. Mediavilla MD, Guezmez A, Ramos S, Kothari L, Garijo F, Sanchez-Barcelo EJ. Effect of melatonin on mammary gland lesions in transgenic mice overexpressing N-ras proto-oncogene. J. Pineal Res. 1997;22:86–94
  97. Rao GN, Ney E, Herbert RA. Effect of melatonin and linoleic acid on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Breast Cancer Res. Treatm. 2000;64:287–296
  98. Mockova K, Mnichova M, Kubatka P, Bojkova B, Ahlers I, Ahlersova E. Mammary carcinogenesis induced in Wistar:Han rats by the combination of ionizing radiation and dimethylbenz(a)anthracene: prevention with melatonin. Neoplasma. 2000;47:227–229
  99. Musatov SV, Anisimov VN, Andre V, Vigreuz C, Godard T, Sichel F. Effects of melatonin on N-nitroso-N-methylurea-induced carcinogenesis in rats and mutagenesis in vitro (Ames test and COMET assay). Cancer Lett. 1999;138:37–44
  100. Bartsch H, Bartsch C, Mecke D, Leppert TH. Differential effect of melatonin on early and advanced passages of a DMBA-induced mammary carcinoma in the female rat. Adv. Pineal Res. 1994;7:247–252
  101. Lissoni P, Barni S, Meregalli S, et al.  Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br. J. Cancer. 1995;71:854–856
  102. Lissoni P. Efficacy of melatonin in the immunotherapy of cancer using interleukin-2. In:  Bartsch C,  Bartsch H,  Blask DE,  Cardinali DP,  Hrushesky WJM,  Mecke D editor. The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer; 2001;p. 463–475
  103. Hrushesky WJM. Melatonin cancer therapy. In:  Bartsch C,  Bartsch H,  Blask DE,  Cardinali DP,  Hrushesky WJM,  Mecke D editor. The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer; 2001;p. 476–508
  104. Karasek M, Kuzdak K, Cywinski J, Zylinska K, Smialowska A, Pluzanska A. Effect of melatonin administration in advanced breast cancer patients—preliminary report. Neuroendocrinol. Lett. 1998;19:15–19
  105. Bartsch C, Bartsch H, Karasek M. Melatonin in clinical oncology. Neroedocrinol. Lett. 2002;23(Suppl 1):30–38
  106. Bartsch C, Bartsch H, Gupta D. Pineal melatonin synthesis and secretion during induction and growth of mammary cancer in female rats. In:  Gupta D,  Wollmann HA,  Ranke MB editor. Neuroendocrinology: new frontiers. London and Tubingen: Brain Research Promotion; 1990;p. 326–332
  107. Bartsch C, Bartsch H, Lippert TH, Gupta D. Effect of the mammary carcinogen 7,12-dimethylbenz[a]anthracene on pineal melatonin biosynthesis, secretion and peripheral metabolism. Neuronedocrinology. 1990;52:538–544
  108. Praast G, Bartsch C, Bartsch H, Mecke D, Lippert TH. Hepatic hydroxylation of melatonin in the rat is induced by phenoobarbital and 7,12-dimethylbenz[a]anthracene-implications for cancer etiology. Experientia. 1995;51:349–355
  109. Bartsch H, Bartsch C, Mecke D. The modulation of melatonin in tumor-bearing animals: underlying mechanisms and possible significance for prognosis. In:  Bartsch C,  Bartsch H,  Blask DE,  Cardinali DP,  Hrushesky WJM,  Mecke D editor. The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer; 2001;p. 197–209
  110. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr. Top. Med. Chem. 2002;2:113–132
  111. Blask DE, Dauchy RT, Sauer LA, Kraus JA, Brainard GC. Light during darkness, melatonin suppression and cancer progression. Neuroendocrinol. Lett. 2002;23(Suppl 2):52–56
  112. Pawlikowski M, Winczyk K, Karasek M. Oncostatic action of melatonin: facts and question marks. Neuroendocrinol. Lett. 2002;23(Suppl 1):24–29
  113. Reiter RJ. The pineal and its hormones in the control of reproduction in mammals. Endocrin. Rev. 1980;1:109–131
  114. Wolden-Hanson T, Mitton DR, McCants RL, et al.  Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology. 2000;141:487–497
  115. Hill SM, Kiefer T, Teplitzky S, Spriggs LL, Ram PT. Modulation of the estrogen response pathway in human breast cancer cells by melatonin. In:  Bartsch C,  Bartsch H,  Blask DE,  Cardinali DP,  Hrushesky WJM,  Mecke D editor. The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer; 2001;p. 343–358
  116. Musatov SA, Anisimov VN, Andre V, et al.  Modulatory effects of melatonin on genotoxic response of reference mutagens in the Ames test and the comet assay. Mutat. Res. 1998;417:75–84
  117. Vijayalaxmi , Reiter RJ, Meltz ML. Melatonin reduces gamma radiation-induced primary DNA damage in human blood lymphocytes. Mutat. Res. 1998;397:203–208
  118. Reiter RJ. Reactive oxygen species, DNA damage, and carcinogenesis: intervention with melatonin. In:  Bartsch C,  Bartsch H,  Blask DE,  Cardinali DP,  Hrushesky WJM,  Mecke D editor. The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer; 2001;p. 442–455
  119. Eck-Enriquez K, Kiefer TL, Spriggs LL, Hill SM. Pathways through which a regimen of melatonin and retinoic acid induced apoptosis in MCF-7 human breast cancer cells. Breast Cancer Res. Treat. 2000;61:229–239
  120. Lissoni P, Rovelli F, Malugani F, Bukovec R, Conti A, Maestroni GJM. Antiangiogenic activity of melatonin in advanced cancer patients. Neuroendocrinol. Lett. 2001;22:45–47
  121. Karbownik M. Potential anticarcinogenic action of melatonin and other antioxidants mediated by antioxidative mechanisms. Neuroendocrinol. Lett. 2002;23(Suppl 1):39–44
  122. Sauer LA, Dauchy RT, Blask DE. Polysaturated fatty acids, melatonin, and cancer prevention. Biochem. Pharmacol. 2001;61:1455–1462
  123. Maestroni GJM. Melatonin and the immune system: therapeutic potential in cancer, viral diseases, and immunodeficiency states. In:  Bartsch C,  Bartsch H,  Blask DE,  Cardinali DP,  Hrushesky WJM,  Mecke D editor. The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer; 2001;p. 384–394
  124. Skwarlo-Sonta K. Melatonin in immunity: comparative aspects. Neurondocrinol. Lett. 2002;23(Suppl 1):61–66
  125. Liu F, Ng TB, Fung MC. Pineal indoles stimulate the gene expression of immunomodulating cytokines. J. Neural Transm. 2001;108:397–405
  126. Anisimov SV, Boheler KR, Anisimov VN. Study on the effect of melatonin on gene expression in mouse heart using microarray technology. Dokl. Russ. Acad. Sci. 2002;383:276–281
  127. Ram PT, Dai J, Yuan L, et al.  Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett. 2002;179:141–150
  128. Rodriguez-Reynoso S, Leal C, Portilla E, Olivares N, Muniz J. Effect of exogenous melatonin on hepatic energetic status during ischemia/reperfusion: possible role of tumornecrosis factor-α and nitric oxide. J. Surg. Res. 2001;100:141–149
  129. Prunett-Marcassus B, Ambid L, Vieguere-Bascands N, Penicaud L, Castella L. Evidence for a direct effect of melatonin on mitochondrial genome expression of Siberian hamster adipocytes. J. Pineal Res. 2001;30:108–115
  130. Michel JJ, Xiong Y. Human CUL-1, but not other cullin family members, selectively interacts with SKP1 to form a complex with SKP2 and cyclin A. Cell Growth Differ. 1998;9:435–449
  131. Krek W. Proteolysis and the G1-S transition: the SCF connection. Curr. Opin. Genet. Dev. 1998;8:36–42
  132. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu. Rev. Cell Dev. Biol. 1999;15:435–467
  133. Burnatowska-Hledin M, Zhao P, Capps B, et al.  VACM-1, a cullin gene family member, regulates cellular signaling. Am. J. Physiol. Cell Physiol. 2000;279(1):C266–273
  134. Hemminki A. The molecular basis and clinical aspects of Peutz-Jeghers syndrome. Cell Mol. Life Sci. 1999;55(5):735–750
  135. Benson B, Matthew MJ, Rodin AE. Studies on a non-melatonin pineal antiginadotropin. Acta Endocrinol. 1972;69:257–266
  136. Blask DE, Vaughan MK, Reiter RE. Pineal peptides and reproduction. In:  Relkin R editors. The pineal gland. Amsterdam: Elsevier; 1983;p. 201–224
  137. Noteborn HPJM, Bartsch H, Bartsch C, et al.  Partial purification of a low molecular weight ovine pineal compound(s) with an inhibiting effect on the growth of human melanoma cells in vitro. J. Neural Transm. 1988;73:135–155
  138. Catrina SB, Catrina AI, Sirzen F, et al.  A cytotoxic, apoptotic, low-molecular weight factor from pineal gland. Life Sci. 1999;65:1047–1057
  139. Bartsch H, Bartsch C, Mecke D, Leppert TH. Serial transplants of DMBA-induced mammary tumours in Fischer rats as model system for human breast cancer: I. Effect of melatonin and pineal extracts on slow- and fast-growing passages—in vivo and in vitro studies. Adv. Pineal Res. 1994;8:473–478
  140. Ebels I, Benson B. A survey of the evidence that melatonin and unidentified pineal substances affect neoplastic growth. In:  Bartsch C,  Bartsch H,  Blask DE,  Cardinali DP,  Hrushesky WJM,  Mecke D editor. The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer; 2001;p. 275–293
  141. Morozov VG, Khavinson VKh. Peptide Bioregulators (25-years Experience of Experimental and Clinical Study). St. Petersburg: Nauka; 1996;
  142. Khavinson VKh, Morozov VG, Anisimov VN. Experimental studies of the pineal gland preparation epithalamin. In:  Bartsch C,  Bartsch H,  Blask DE,  Cardinali DP,  Hrushesky WJM,  Mecke D editor. The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer; 2001;p. 294–306
  143. Dilman VM, Anisimov VN, Ostroumova MN, Khavinson VKh, Morozov VG, Azarova MA. Study on the anti-tumor effect of polypeptide pineal extract. Oncology. 1979;36:274–280
  144. Anisimov VN, Khavinson VKh. Effect of polypeptide pineal preparation on life span and spontaneous tumor incidence in old female rats. Dokl. Akad. Nauk. USSR. 1991;319:250–254
  145. Anisimov VN, Khavinson VKh, Morozov VG. Carcinogenesis and aging. IV. Effect of low-molecular weight factors of thymus, pineal gland and anterior hypothalamus on immunity, tumor incidence and life span of C3H/Sn mice. Mech. Ageing Dev. 1982;19:245–258
  146. Anisimov VN, Loktionov AS, Khavinson VKh, Morozov VG. Effect of low-molecular-weight factors of thymus and pineal gland on life span and spontaneous tumour development in female of different age. Mech. Ageing Dev. 1989;49:245–257
  147. Anisimov VN, Ostroumova MN, Dilman VM. Inhibition of carcinogenic effect of 7,12-dimethylbenz(a)anthracene with buformin, diphenylhydantoin, polypeptide pineal extract and l-DOPA in female rats. Bull. Exp. Biol. Med. 1980;89:723–725
  148. Anisimov VN, Miretski GI, Morozov VG, Khavinson VKh. Effect of polypeptide factors of thymus and epiphysis on radiation carcinogenesis. Bull. Exp. Biol. Med. 1982;94:26–29
  149. Anisimov VN, Khavinson VKh, Morozov VG. Twenty years of study on effects of pineal peptide preparation: epithalamin in experimental gerontology and oncology. Ann. N.Y. Acad. Sci. 1994;719:483–493
  150. Slepushkin VD, Anisimov VN, Khavinson VKh, Morozov VG, Vasiliev NV, Kosykh VA. Pineal gland, immunity and cancer (Theoretical and clinical aspects). Tomsk: Tomsk University; 1990;
  151. Khavinson VKh, Izmailov DM, Obukhova LK, Malinin VV. Effect of epithalon on lifespan increase in Drosophila melanogaster. Mech. Ageing Dev. 2000;120:141–149
  152. Anisimov VN, Khavinson VKh, Alimova IN, Provinciali M, Mancini R, Franceschi C. Epitalon inhibits development of tumors and expression of HER-2/neu oncogene in mammary tumors in transgenic mice with accelerated aging. Bull. Exp. Biol. Med. 2002;132:56–59
  153. Anisimov VN, Arutjunyan AV, Khavinson VKh. Effects of pineal peptide preparation Epithalamin on free radical processes in humans and animals. Neuroendocrinol. Lett. 2001;22:11–20
  154. Khavinson VKh, Goncharova ND, Lapin BA. Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuroendocrinol. Lett. 2001;22:251–254
  155. Khavinson VKh, Kvetnoi IM, Popuchiev VV, Yuzhakov VV, Kotlova LN. Effect of pineal peptides on neuroendocrine system after pinealectomy. Arkhiv. Pathol. 2001;63(3):18021
  156. Khavinson VKh, Yakovleva ND, Popuchiev VV, Kvetnoi IM, Ymanokhina RP. Reparative effect of epitalon on pineal ultrastructure in gamma-irradiated rats. Bull. Exp. Biol. Med. 2001;131:81–85
  157. Anisimov VM, Khavinson VKh, Mikhalski AI, Yashin AI. Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. Mech. Ageing Dev. 2001;122:41–68
  158. Rosenfeld SV, Togo EF, Mikheev VS, et al.  Effect of Epitalon on chromosome lesion incidence in senescence accelerated (SAM) mice. Bull. Exp. Biol. Med. 2002;133:320–322
  159. Anisimov SV, Boheler KR, Khavinson VKh, Anisimov VN. Study on the effect of peptides Vilon and Epitalon on gene expression in mouse heart using microarray technology. Bull. Exp. Biol. Med. 2002;133:340–347
  160. Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA. Inhibitory effect of peptide Epitalon on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats. Cancer Lett. 2002;183:1–8
  161. Erren TC. Does light cause internal cancers?—The problem and challenge of an ubiquitous exposure. Neuroendocrinol. Lett. 2002;23(Suppl 2):61–70
  162. Poole C. The darkness at the end of the tunnel: summary and evaluation of an International Symposium on Light Endocrine Systems and Cancer. Neuroendocrinol. Lett. 2002;23(Suppl 2):71–78
  163. Anisimov VN, Hansen J. Light, endocrine systems and cancer—A meeting report. Neuroendocrinol. Lett. 2002;23(Suppl 2):84–87

PII: S1040-8428(03)00021-0

doi: 10.1016/S1040-8428(03)00021-0

Critical Reviews in Oncology / Hematology
Volume 46, Issue 3 , Pages 221-234 , June 2003

Article Tools